N/A
N=5
Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation
Papillary Thyroid Cancer · Papillary Thyroid Microcarcinoma
Bottom Line
View on ClinicalTrials.gov: NCT04129411 ↗Enrolled (actual)
5
Serious AEs
0.0%
Results posted
May 2025
Primary outcome: Primary: Changes in Thyroid Nodule Size — 0.241361; 0.954909; 0.422121; 0.104143 mL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- RFA (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- May 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Changes in Thyroid Nodule Size |
0.241361; 0.954909; 0.422121; 0.104143; 0.040035 | — |
| SECONDARY Pain Related to RFA Procedure |
1 | — |
| SECONDARY Development of Lymph Node Involvement |
— | — |
| SECONDARY Development of Distant Metastasis |
— | — |
| SECONDARY Safety of the RFA Procedure |
— | — |
| SECONDARY Change in Thyroid Status |
4; 0; 1; 0; 5; 0 | — |
Summary
Investigators intend to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.
Eligibility Criteria
Inclusion Criteria
- Are adults
- Nodule with Papillary thyroid carcinoma meeting the below criteria:
- Diagnosed by fine needle aspiration (FNA) cytology.
- Size < 1.5 cm
- Non-surgical therapy is considered acceptable by the treating physician
- Radiology evaluation deems the lesion amenable to RFA therapy with minimal risk of complication
Exclusion Criteria
- Clinical evidence for a multifocal papillary thyroid malignancy
- Clinical evidence for local or distant metastatic disease
- Pregnancy
- Vocal cord paralysis on contralateral side
- Coagulopathy or patients on anticoagulation therapy
- Patients with prior neck surgery or neck radiation
- Patients with neck anatomy that precludes easy access by RFA
- Patients with comorbidities deemed too high of a risk for general anesthesia
- Treatment with another investigational drug or intervention (within 6 weeks of planned RFA).
- Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
Data sourced from ClinicalTrials.gov (NCT04129411). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.